Alnylam Pharmaceuticals, Inc.
ALNYNasdaqCIK 1178670HealthcareFiscal year ends Dec 31
All transactions: 6
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2017-05-31 | Sanofi10% owner | Purchase | 297,501 | $71.87 | $21.4m | Form 4 |
| 2016-02-01 | Sanofi10% owner | Purchase | 205,030 | $69.75 | $14.3m | Form 4 |
| 2015-01-29 | Sanofi10% owner | Purchase | 97,118 | $95.00 | $9.2m | Form 4 |
| 2015-01-26 | Sanofi10% owner | Purchase | 647,448 | $95.00 | $61.5m | Form 4 |
| 2015-01-22 | Sanofi10% owner | Purchase | 196,251 | $9,317.00 | $1.83bn | Form 4 |
| 2015-01-22 | Sanofi10% owner | Purchase | 196,251 | $93.17 | $18.3m | Form 4/A |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 31, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.